
CHMP May 2026: Eight medicines recommended for approval and Wegovy goes oral
EMA’s CHMP in May 2026 recommended eight new medicines (including Jascayd for IPF/PPF), three hybrid medicines, and a positive biosimilar opinion for Vislyfa; it issued a negative opinion for Deqtynet, approved extensions of indications for several medicines, and withdrew initial authorisation applications for Orblid and Veblocema. The committee also endorsed Wegovy’s extension to a daily oral tablet and published accompanying updates and statistics (eight positive opinions on new medicines, one negative, and eighteen positive opinions on extensions in 2026).













